{
    "ticker": "CYADY",
    "name": "Celyad Oncology SA",
    "description": "Celyad Oncology SA is a clinical-stage biopharmaceutical company focused on the development of innovative cell therapy treatments for cancer. Founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, Celyad is at the forefront of developing chimeric antigen receptor T-cell (CAR-T) therapies that aim to provide new treatment options for patients with hematological malignancies and solid tumors. The company's lead product candidates include CYAD-01, which targets the NKG2D receptor for the treatment of non-Hodgkin lymphoma and other cancers, and CYAD-211, an innovative approach that incorporates a dual-targeting strategy. Celyad's proprietary technology platform enables the engineering of T-cells with the potential to enhance the body's immune response against cancer cells. With a commitment to advancing cancer treatment, Celyad is actively engaged in clinical trials and collaborations aimed at bringing transformative therapies to market. The company is dedicated to improving the lives of patients through innovative science and clinical excellence, striving to make a meaningful impact in the fight against cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Mont-Saint-Guibert, Belgium",
    "founded": "2007",
    "website": "https://www.celyad.com",
    "ceo": "Christian Homsy",
    "social_media": {
        "twitter": "https://twitter.com/CelyadOncology",
        "linkedin": "https://www.linkedin.com/company/celyad-oncology/"
    },
    "investor_relations": "https://investors.celyad.com",
    "key_executives": [
        {
            "name": "Christian Homsy",
            "position": "CEO"
        },
        {
            "name": "David Gilham",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy Products",
            "products": [
                "CYAD-01",
                "CYAD-211"
            ]
        }
    ],
    "seo": {
        "meta_title": "Celyad Oncology SA | Innovative Cell Therapy for Cancer",
        "meta_description": "Explore Celyad Oncology SA, a leader in cell therapy for cancer treatment. Discover their innovative therapies and commitment to improving patient outcomes.",
        "keywords": [
            "Celyad Oncology",
            "Cell Therapy",
            "CAR-T",
            "Cancer Treatment",
            "Biotechnology",
            "CYAD-01",
            "CYAD-211"
        ]
    },
    "faq": [
        {
            "question": "What is Celyad Oncology known for?",
            "answer": "Celyad Oncology is known for developing innovative cell therapy treatments for cancer, particularly CAR-T therapies."
        },
        {
            "question": "Who is the CEO of Celyad Oncology?",
            "answer": "Christian Homsy is the CEO of Celyad Oncology SA."
        },
        {
            "question": "Where is Celyad Oncology headquartered?",
            "answer": "Celyad Oncology is headquartered in Mont-Saint-Guibert, Belgium."
        },
        {
            "question": "What are Celyad Oncology's main products?",
            "answer": "Celyad Oncology's main products include CYAD-01 and CYAD-211, both targeting cancer treatment."
        },
        {
            "question": "When was Celyad Oncology founded?",
            "answer": "Celyad Oncology was founded in 2007."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGEN",
        "KITE"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "MRNA"
    ]
}